Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43858   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-004089-33
    Sponsor's Protocol Code Number:DYN101-C101
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-06-18
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2018-004089-33
    A.3Full title of the trial
    A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations in DNM2 or MTM1
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An early phase human drug trial (called phase 1/2) to investigate DYN101 in patients ≥ 16 years of age with a rare muscle disease group called the centronuclear myopathies caused by genetic changes in DNM2 or MTM1 for the drug’s safety, tolerability, how the body processes the drug as well as interactions of the drug with the body and preliminary effects of the drug.
    A.3.2Name or abbreviated title of the trial where available
    Research Using an Investigational Treatment for CNM (Unite-CNM)
    A.4.1Sponsor's protocol code numberDYN101-C101
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDynacure
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDynacure
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDynacure
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressBioparc 3, 850 Boulevard Sébastien Brant
    B.5.3.2Town/ city67400 Illkirch – Graffenstaden
    B.5.3.3Post code67400
    B.5.3.4CountryFrance
    B.5.4Telephone number+336 98 75 98 44
    B.5.6E-mailChris.Freitag@Dynacure.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDYN101
    D.3.2Product code DYN101
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDYN101
    D.3.9.2Current sponsor codeDYN101
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Centronuclear myopathies (CNMs) in patients ≥ 16 years of age with mutations in DNM2 or MTM1
    E.1.1.1Medical condition in easily understood language
    Centronuclear myopathies (CNMs) in patients ≥ 16 years of age with mutations in DNM2 or MTM1
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10028640
    E.1.2Term Myopathies
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the safety and tolerability of 3 single ascending dose (SAD) levels and 3 multiple ascending dose (MAD) levels of DYN101
    E.2.2Secondary objectives of the trial
    • To assess the pharmacokinetics (PK) of SAD and MAD of DYN101.
    • To explore target engagement in muscle of DYN101.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female aged ≥ 16 years of age* on the date of signing the
    main ICF. The first subject (i.e. the sentinel subject) in each cohort must
    be ≥ 18 years of age. *for Germany, the subject must be ≥ 18 years of
    age in accordance with local and national regulations.
    2. Have a documented mutation in DNM2 or MTM1.
    3. Platelet count > 150,000/μL,
    4. Have a symptomatic CNM in the opinion of the investigator, at least
    mild to moderately affected, i.e. showing clinical symptoms in at least 2
    of the 4 relevant domains that will be investigated in this trial
    (respiratory function, muscle strength and muscle function, dysphagia), and be
    ambulatory, i.e. being able to walk 10 steps, if needed with
    support/assisted. If a subject is non-ambulatory but highly functioning
    in the view of the investigator, he/she may be included following
    discussion with the sponsor.
    5. Have an understanding, ability and willingness to fully comply with
    visit frequency, trial procedures and restrictions, including contraceptive
    requirements.
    6. Able to provide written, signed and dated informed consent/assent to
    participate in the trial. Parental consent (one or both parents) and an
    assent for subjects < 18 years may be required per local legislation.
    E.4Principal exclusion criteria
    1. Clinically significant liver disease.
    2. Clinically significant renal disease.
    3. Presence of significant co-morbidities or conditions other than CNM or
    clinically significant findings during screening of medical history,
    physical examination, laboratory testing, vital signs or ECG recording for
    which, in the opinion of the investigator and the medical monitor,
    participation would not be in the best interest of the subject (e.g.
    compromise the safety or well-being) or that could prevent, limit, or
    confound the protocol-specified assessments (e.g. taking a muscle
    biopsy).
    4. For female subjects of child-bearing potential: pregnant or
    breastfeeding, or planning to become pregnant during the trial.
    5. Current or past abuse of alcohol or recreational/narcotic drugs (with
    the exception of caffeine and nicotine), which in the investigator's
    opinion would compromise the subject's safety and/or compliance with
    the trial procedures.
    6. Currently enrolled in another investigational trial or scheduled to
    participate in another trial whilst participating in this trial.
    7. Current or relevant history of physical or psychiatric illness, any
    medical disorder that may require treatment or make the subject
    unlikely to fully complete the trial, or any condition that presents undue
    risk from the IMP or procedures.
    8. Intake of any disallowed therapies as noted in the protocol within 12
    weeks before the planned first IMP administration.
    9. Known or suspected intolerance or hypersensitivity to IMP ingredients
    or closely-related compounds, or history of a significant allergic reaction
    to IMP ingredients as determined by the investigator, such as
    anaphylaxis requiring hospitalization.
    10. Legally incapacitated or have limited legal capacity. Lack of mental
    capacity to fully understand the protocol requirements and complete all
    study required procedures.
    E.5 End points
    E.5.1Primary end point(s)
    Comparison of adverse event (AE, SAE, AESI) frequency and severity by dose (cohort), for single or multiple administration, and by mutated gene (subcohort) and overall using the Safety Analysis set following 12 weeks of MAD treatment and after 24 weeks of MAD treatment (12 weeks in the MAD part + 12 weeks in the MAD extension part; Week 25 visit) or discontinued earlier.
    E.5.1.1Timepoint(s) of evaluation of this end point
    All visits from baseline to W25 visit and safety End-of-Treatment follow up visit 3 months after last dose
    E.5.2Secondary end point(s)
    • Comparison of means for PK parameters of DYN101 in plasma (AUCτ,
    AUClast, AUC∞, Rac(AUC), Rac(Cmax), Cmax, Cav SS, CL, λz, t1/2, tmax,
    Vz) by dose (cohort), for single or multiple administration, and by
    mutated gene (sub-cohort) and overall using the Pharmacokinetic Set.
    • Comparison of geometric means for PK parameters of DYN101 in
    plasma (Cmax and AUCs) by dose (cohort), for single or multiple
    administration, and by mutated gene (sub-cohort) and overall using the
    Pharmacokinetic Set.
    • Comparison of means on DNM2 mRNA levels and DYN101 concentrations using muscle biopsy data by dose (cohort), for single or
    multiple administration, and by mutated gene (sub-cohort) and overall
    using the Pharmacokinetic Set.
    • Comparison of means change from baseline in vital signs, laboratory
    data, and ECG by dose (cohort), for single or multiple administration,
    and by mutated gene (sub-cohort) and overall.
    E.5.2.1Timepoint(s) of evaluation of this end point
    SAD part: Pre-dose (0h), 30 min post start of infusion, immediately after end of infusion, 1h, 3h, 7h, 23h, 47h, 167h
    post-dose then 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks post-dose
    MAD W1 - Pre-dose (0h), 30 min post start of infusion, immediately after end of infusion, 1h, 3h, 7h, 23h, 47h, 71h ( 71h timepoint pre-loading dose) and 167h post-dose
    MAD W12 - Pre-dose, 30 min post start of infusion, immediately after end of infusion, 1h, 3h, 7h, 23h, 71h and 167h post-dose of Week 12, Day 1 MAD W25 - 167h post-dose of Week 24*
    Muscle Biopsies:
    2 time points: At SAD baseline (or at MAD baseline for replaced subjects who did not participate in SAD) and At the end of the 12 weeks MAD part (W13)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Belgium
    Denmark
    France
    Germany
    Netherlands
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last visit of the last subject
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days6
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 6
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 6
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 10
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 2
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 16
    F.4.2.2In the whole clinical trial 18
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The subject will receive other treatment and/or have access to other appropriate care by his doctor.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-07-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-07-01
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2022-06-22
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 12:45:04 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA